A U.S. District Court judge has dissolved...

A U.S. District Court judge has dissolved a temporary restraining order that prevented Genetics Institute, a Cambridge, Mass.-based biotechnology firm, from manufacturing and selling an anti-anemia drug it is developing. The judge urged a speedy trial in the matter. Genetics Institute is involved in a series of patent infringement cases with Amgen, a Thousand Oaks-based biotechnology company that is developing its own version of erythropoietin. Amgen and Genetics Institute have applied to the Food and Drug Administration for approval to sell the drug here, and both, through partners, are trying to break into the European market.